EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds through analysis of U.S. longitudinal ...
Demonstrates PPARG inhibition as a potential strategy to overcome immune resistance in advanced UC − Supports the planned ...
T3D-959, an oral dual delta/gamma peroxisome proliferator-activated nuclear receptor (PPAR) agonist, has shown promise in a phase 2 randomized, placebo-controlled study of adults with mild-to-moderate ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This abstract does not include a full text component.
Annals of Nutrition & Metabolism, Vol. 75, No. 3 (2019), p. 197 (1 page) Liang J, Lan J, Li M, Wang F. Associations of Leptin Receptor and Peroxisome Proliferator-Activated Receptor Gamma ...
FX-909, the first small molecule targeting PPARG to be tested in humans, showed monotherapy activity in advanced urothelial carcinoma with a ...
Correlative analyses between EGFR pathways and stroma-tumor profiles in head and neck cancer patients (HNSCC) on postoperative radiotherapy plus cisplatin (PORTc) plus or minus gefitinib ...
The Journal of Parasitology, Vol. 106, No. 5 (OCTOBER 2020), pp. 564-571 (8 pages) ...
Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the U.S. Despite recent advances, the five-year survival rate for metastatic UC ...
Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback